Hyundai Pharmaceutical Co., Ltd. Statistics
Want to see KR:004310 full AI Analyst Report?
Hyundai Pharmaceutical Co., Ltd. (004310) Stock Statistics & Valuation Metrics
Total Valuation
Hyundai Pharmaceutical Co., Ltd. has a market cap or net worth of KRW 201.27B. The enterprise value is KRW 224.18B.
- Market Cap
- KRW 201.27B
- Enterprise Value
- KRW 224.18B
Share Statistics
Hyundai Pharmaceutical Co., Ltd. has 32,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 32,000,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.26%
Financial Efficiency
Hyundai Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 2.36%.
- Return on Equity (ROE)
- 0.03
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 2.36%
- Return on Capital Employed (ROCE)
- 0.03
- Revenue Per Employee
- 480.69M
- Profits Per Employee
- 6.31M
- Employee Count
- 399
- Asset Turnover
- 1.15
- Inventory Turnover
- 3.48
Valuation Ratios
The current PE Ratio of Hyundai Pharmaceutical Co., Ltd. is 50.23. Hyundai Pharmaceutical Co., Ltd.’s PEG ratio is 0.24.
- PE Ratio
- 50.23
- PS Ratio
- 0.91
- PB Ratio
- 1.45
- Price to FCF
- 27.13
- Price to Operating Cash Flow
- 18.27
- PEG Ratio
- 0.24
Income Statement
In the last 12 months, Hyundai Pharmaceutical Co., Ltd. had revenue of 191.79B and earned 2.52B in profits. Earnings per share was 96.28.
- Revenue
- 191.79B
- Gross Profit
- 78.23B
- Operating Income
- 3.30B
- Pretax Income
- 2.31B
- Net Income
- 2.52B
- EBITDA
- 7.58B
- Earnings Per Share (EPS)
- 96.28
Cash Flow
In the last 12 months, operating cash flow was 10.27B and capital expenditures -3.35B, giving a free cash flow of 6.92B billion.
- Operating Cash Flow
- 10.27B
- Free Cash Flow
- 6.92B
- Free Cash Flow per Share
- 223.72
Dividends & Yields
Hyundai Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 0.46%
- Dividend Per Share
- ―
- Dividend Yield
- 0.46%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.69%
- Earnings Yield
- 1.92%
Stock Price Statistics
- Beta
- 0.60
- 52-Week Price Change
- 61.01%
- 50-Day Moving Average
- 7979.60
- 200-Day Moving Average
- 7983.68
- Relative Strength Index (RSI)
- 40.61
- Average Volume (3m)
- 4.07M
Important Dates
Hyundai Pharmaceutical Co., Ltd. upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 15, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Hyundai Pharmaceutical Co., Ltd. as a current ratio of 1.13, with Debt / Equity ratio of 60.98%
- Current Ratio
- 1.13
- Quick Ratio
- 0.68
- Debt to Market Cap
- 0.52
- Net Debt to EBITDA
- 6.28
- Interest Coverage Ratio
- 1.75
Taxes
In the past 12 months, Hyundai Pharmaceutical Co., Ltd. has paid -209.50M in taxes.
- Income Tax
- -209.50M
- Effective Tax Rate
- -0.09
Enterprise Valuation
Hyundai Pharmaceutical Co., Ltd. EV to EBITDA ratio is 21.64, with an EV/FCF ratio of 32.47.
- EV to Sales
- 1.08
- EV to EBITDA
- 21.64
- EV to Free Cash Flow
- 32.47
- EV to Operating Cash Flow
- 21.87
Balance Sheet
Hyundai Pharmaceutical Co., Ltd. has KRW 22.72B in cash and marketable securities with KRW 49.54B in debt, giving a net cash position of -KRW 26.81B billion.
- Cash & Marketable Securities
- KRW 22.72B
- Total Debt
- KRW 49.54B
- Net Cash
- -KRW 26.81B
- Net Cash Per Share
- -KRW 837.91
- Tangible Book Value Per Share
- KRW 3,901.28
Margins
Gross margin is 35.56%, with operating margin of 2.59%, and net profit margin of 1.74%.
- Gross Margin
- 35.56%
- Operating Margin
- 2.59%
- Pretax Margin
- 2.29%
- Net Profit Margin
- 1.74%
- EBITDA Margin
- 5.01%
- EBIT Margin
- 2.66%
Analyst Forecast
The average price target for Hyundai Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 11.35%
- EPS Growth Forecast
- 204.54%
Scores
- Smart Score
- ―
- AI Score
- 52

